Literature DB >> 24054808

Single-lung transplantation can be performed with acceptable outcomes using selected donors with heavy smoking history.

Sharven Taghavi1, Senthil N Jayarajan, Eugene Komaroff, Tetsuya Horai, Stacey Brann, Namrata Patel, Francis Cordova, Gerard Criner, T Sloane Guy, Yoshiya Toyoda.   

Abstract

BACKGROUND: We attempt to determine if adult, single-lung transplantation could be performed with acceptable results in heavy-smoking donors (HSDs; > 20 pack-years).
METHODS: The United Network of Organ Sharing database was examined for adult single-lung transplantation from 2005 to 2011.
RESULTS: Of the 3,704 single-lung transplantations, 498 (13.4%) were from HSDs. The 2 groups were similar in recipient age (60.6 vs. 60.7 years, p = 0.20), male gender (61.3% vs. 59.8%, p = 0.54), ischemic time (4.1 vs. 4.2 hours, p = 0.11), and pre-transplant forced expiratory volume in 1 second (FEV1; 41.1% vs. 40.0% predicted). Recipients of HSDs had lower lung allocation score (39.7 vs. 38.0, p = 0.02), less human leukocyte antigen mismatches (4.6 vs. 4.5, p = 0.01), and higher class I panel reactive antibody (2.9% vs. 3.8%, p < 0.001). HSDs were older (33.0 vs. 41.3 years, p < 0.001) and less likely male (62.5 vs. 56.0%, p = 0.01). Recipients with HSDs had longer length of stay (20.5 vs. 23.0 days, p < 0.001) and lower peak FEV1 after single-lung transplantation (80.1% vs. 73.4%, p < 0.001). Freedom from bronchiolitis obliterans syndrome (p = 0.64), post-single-lung transplantation decrement in FEV1 (p = 0.07), and median survival (1,516 vs. 1,488 days, p = 0.10) were similar. Multivariable analysis found receiving lungs from actively smoking HSDs was associated with mortality (hazard ratio [HR], 1.23, 95% confidence interval [CI], 1.05-1.45; p = 0.01). Use of HSDs who were not actively smoking was not associated with mortality (HR, 0.84; 95% CI, 0.59-1.19; p = 0.33). Mortality was associated with recipient age, longer ischemic time, race mismatch, class I panel reactive antibody > 10%, mechanical ventilation, and extracorporeal membrane oxygenation as a bridge to transplantation.
CONCLUSIONS: Although single-lung transplantation with actively smoking HSDs results in worse results, outcomes are acceptable and should continue to be considered.
© 2013 International Society for Heart and Lung Transplantation. All rights reserved.

Entities:  

Keywords:  donor selection; heavy-smoking donors; outcomes; single-lung transplant; survival; tobacco

Mesh:

Year:  2013        PMID: 24054808     DOI: 10.1016/j.healun.2013.05.018

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  6 in total

Review 1.  Evaluation and Management of the Potential Lung Donor.

Authors:  Andrew Courtwright; Edward Cantu
Journal:  Clin Chest Med       Date:  2017-08-31       Impact factor: 2.878

Review 2.  Ex vivo lung perfusion.

Authors:  Tiago N Machuca; Marcelo Cypel
Journal:  J Thorac Dis       Date:  2014-08       Impact factor: 2.895

Review 3.  Procurement of lungs from brain-dead donors.

Authors:  Prasad Krishnan; Sahar-Al-Sadat Sahar Saddoughi
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-03-19

Review 4.  Lung cancer: a rare indication for, but frequent complication after lung transplantation.

Authors:  Dirk Van Raemdonck; Robin Vos; Jonas Yserbyt; Herbert Decaluwe; Paul De Leyn; Geert M Verleden
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

5.  Comparison of open gastrostomy tube to percutaneous endoscopic gastrostomy tube in lung transplant patients.

Authors:  Sharven Taghavi; Vishnu Ambur; Senthil Jayarajan; John Gaughan; Yoshiya Toyoda; Elizabeth Dauer; Lars Ola Sjoholm; Abhijit Pathak; Thomas Santora; Amy J Goldberg
Journal:  Ann Med Surg (Lond)       Date:  2015-12-23

6.  Short- and Long-Term Impact of Smoking Donors in Lung Transplantation: Clinical and Pathological Analysis.

Authors:  Marco Schiavon; Andrea Lloret Madrid; Francesca Lunardi; Eleonora Faccioli; Giulia Lorenzoni; Giovanni Maria Comacchio; Alessandro Rebusso; Andrea Dell'Amore; Marco Mammana; Samuele Nicotra; Fausto Braccioni; Dario Gregori; Emanuele Cozzi; Fiorella Calabrese; Federico Rea
Journal:  J Clin Med       Date:  2021-05-28       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.